Literature DB >> 18270700

The value of incomplete mouse models of Alzheimer's disease.

Rebecca Radde1, Cecilia Duma, Michel Goedert, Mathias Jucker.   

Abstract

To study Alzheimer's disease (AD), a variety of mouse models has been generated through the overexpression of the amyloid precursor protein and/or the presenilins harboring one or several mutations found in familial AD. With aging, these mice develop several lesions similar to those of AD, including diffuse and neuritic amyloid deposits, cerebral amyloid angiopathy, dystrophic neurites and synapses, and amyloid-associated neuroinflammation. Other characteristics of AD, such as neurofibrillary tangles and nerve cell loss, are not satisfactorily reproduced in these models. Mouse models that recapitulate only specific aspects of AD pathogenesis are of great advantage when deciphering the complexity of the disease and can contribute substantially to diagnostic and therapeutic innovations. Incomplete mouse models have been key to the development of Abeta42-targeted therapies, as well as to the current understanding of the interrelationship between cerebral beta-amyloidosis and tau neurofibrillary lesions, and are currently being used to develop novel diagnostic agents for in vivo imaging.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18270700     DOI: 10.1007/s00259-007-0704-y

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  41 in total

1.  APP transgenic mice Tg2576 accumulate Abeta peptides that are distinct from the chemically modified and insoluble peptides deposited in Alzheimer's disease senile plaques.

Authors:  Walter Kalback; M Desiree Watson; Tyler A Kokjohn; Yu-Min Kuo; Nicole Weiss; Dean C Luehrs; John Lopez; Daniel Brune; Sangram S Sisodia; Matthias Staufenbiel; Mark Emmerling; Alex E Roher
Journal:  Biochemistry       Date:  2002-01-22       Impact factor: 3.162

2.  Cerebral hemorrhage after passive anti-Abeta immunotherapy.

Authors:  M Pfeifer; S Boncristiano; L Bondolfi; A Stalder; T Deller; M Staufenbiel; P M Mathews; M Jucker
Journal:  Science       Date:  2002-11-15       Impact factor: 47.728

3.  Abeta deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse.

Authors:  M C Irizarry; F Soriano; M McNamara; K J Page; D Schenk; D Games; B T Hyman
Journal:  J Neurosci       Date:  1997-09-15       Impact factor: 6.167

Review 4.  Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective.

Authors:  Rudolph E Tanzi; Lars Bertram
Journal:  Cell       Date:  2005-02-25       Impact factor: 41.582

5.  Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP.

Authors:  J Lewis; D W Dickson; W L Lin; L Chisholm; A Corral; G Jones; S H Yen; N Sahara; L Skipper; D Yager; C Eckman; J Hardy; M Hutton; E McGowan
Journal:  Science       Date:  2001-08-24       Impact factor: 47.728

6.  Neurotoxic effects of thioflavin S-positive amyloid deposits in transgenic mice and Alzheimer's disease.

Authors:  B Urbanc; L Cruz; R Le; J Sanders; K Hsiao Ashe; K Duff; H E Stanley; M C Irizarry; B T Hyman
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-09       Impact factor: 11.205

7.  Abeta40 inhibits amyloid deposition in vivo.

Authors:  Jungsu Kim; Luisa Onstead; Suzanne Randle; Robert Price; Lisa Smithson; Craig Zwizinski; Dennis W Dickson; Todd Golde; Eileen McGowan
Journal:  J Neurosci       Date:  2007-01-17       Impact factor: 6.167

Review 8.  Mechanism of cerebral beta-amyloid angiopathy: murine and cellular models.

Authors:  Martin C Herzig; William E Van Nostrand; Mathias Jucker
Journal:  Brain Pathol       Date:  2006-01       Impact factor: 6.508

9.  Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography.

Authors:  Jun Maeda; Bin Ji; Toshiaki Irie; Takami Tomiyama; Masahiro Maruyama; Takashi Okauchi; Matthias Staufenbiel; Nobuhisa Iwata; Maiko Ono; Takaomi C Saido; Kazutoshi Suzuki; Hiroshi Mori; Makoto Higuchi; Tetsuya Suhara
Journal:  J Neurosci       Date:  2007-10-10       Impact factor: 6.167

Review 10.  A century of Alzheimer's disease.

Authors:  Michel Goedert; Maria Grazia Spillantini
Journal:  Science       Date:  2006-11-03       Impact factor: 47.728

View more
  29 in total

1.  Arginine deprivation and immune suppression in a mouse model of Alzheimer's disease.

Authors:  Matthew J Kan; Jennifer E Lee; Joan G Wilson; Angela L Everhart; Candice M Brown; Andrew N Hoofnagle; Marilyn Jansen; Michael P Vitek; Michael D Gunn; Carol A Colton
Journal:  J Neurosci       Date:  2015-04-15       Impact factor: 6.167

Review 2.  Clinico-pathologic function of cerebral ABC transporters - implications for the pathogenesis of Alzheimer's disease.

Authors:  Jens Pahnke; Olaf Wolkenhauer; Markus Krohn; Lary C Walker
Journal:  Curr Alzheimer Res       Date:  2008-08       Impact factor: 3.498

3.  Longitudinal study of differential protein expression in an Alzheimer's mouse model lacking inducible nitric oxide synthase.

Authors:  Michael D Hoos; Brenna M Richardson; Matthew W Foster; Angela Everhart; J Will Thompson; M Arthur Moseley; Carol A Colton
Journal:  J Proteome Res       Date:  2013-09-18       Impact factor: 4.466

4.  GSPE interferes with tau aggregation in vivo: implication for treating tauopathy.

Authors:  Ismael Santa-Maria; Carmen Diaz-Ruiz; Hanna Ksiezak-Reding; Alice Chen; Lap Ho; Jun Wang; Giulio Maria Pasinetti
Journal:  Neurobiol Aging       Date:  2011-11-04       Impact factor: 4.673

Review 5.  Transgenic models of Alzheimer's disease: better utilization of existing models through viral transgenesis.

Authors:  Thomas L Platt; Valerie L Reeves; M Paul Murphy
Journal:  Biochim Biophys Acta       Date:  2013-04-22

6.  Modeling presenilin-dependent familial Alzheimer's disease: emphasis on presenilin substrate-mediated signaling and synaptic function.

Authors:  Angèle T Parent; Gopal Thinakaran
Journal:  Int J Alzheimers Dis       Date:  2010-07-20

7.  Pathological Hallmarks, Clinical Parallels, and Value for Drug Testing in Alzheimer's Disease of the APP[V717I] London Transgenic Mouse Model.

Authors:  An Tanghe; Annelies Termont; Pascal Merchiers; Stephan Schilling; Hans-Ulrich Demuth; Louise Scrocchi; Fred Van Leuven; Gerard Griffioen; Tom Van Dooren
Journal:  Int J Alzheimers Dis       Date:  2010-09-02

8.  The presenilin-1 ΔE9 mutation results in reduced γ-secretase activity, but not total loss of PS1 function, in isogenic human stem cells.

Authors:  Grace Woodruff; Jessica E Young; Fernando J Martinez; Floyd Buen; Athurva Gore; Jennifer Kinaga; Zhe Li; Shauna H Yuan; Kun Zhang; Lawrence S B Goldstein
Journal:  Cell Rep       Date:  2013-11-14       Impact factor: 9.423

9.  Diminished perisomatic GABAergic terminals on cortical neurons adjacent to amyloid plaques.

Authors:  Virginia Garcia-Marin; Lidia Blazquez-Llorca; José-Rodrigo Rodriguez; Susana Boluda; Gerard Muntane; Isidro Ferrer; Javier Defelipe
Journal:  Front Neuroanat       Date:  2009-11-20       Impact factor: 3.856

Review 10.  Heterogeneity of microglial activation in the innate immune response in the brain.

Authors:  Carol A Colton
Journal:  J Neuroimmune Pharmacol       Date:  2009-08-05       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.